Skip to Main Content

Phase 2/3 Study Evaluating the Safety and Efficacy of PTX-022 in Treatment of Adults With Pachyonychia Congenita

Conditions

Diseases of the Integumentary System

Phase II-III

What is the purpose of this trial?

Brief Summary:

This study evaluates the safety and efficacy of PTX-022, topical rapamycin, in the treatment of adults with moderate to severe Pachyonychia Congenita.

This study includes four-parts, and if a participant completes all parts, the participant will have received at least 3-months of PTX-022 treatment.

  • Trial with
    Palvella Therapeutics, Inc.
  • Start Date
    06/16/2019
  • End Date
    12/30/2019
Trial Image

For more information about this study, contact:

Mahin Dawood

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    08/06/2019
  • Study HIC
    #2000024725